A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To assess the anti-tumor efficacy, as determined by objective response rate, of intravenous CP-675,206 administered at a dose of 15 mg/kg every 90 days to patients with relapsed or refractory advanced melanoma

Outcome Time Frame:

Tumor response is assessed every 2-3 months until disease progression

Safety Issue:

No

Authority:

United States: Food and Drug Administration

Study ID:

A3671008

NCT ID:

NCT00254579

Start Date:

December 2005

Completion Date:

December 2009

Related Keywords:

• Refractory Melanoma
• refractory melanoma
• malignant melanoma
• Melanoma